Challenges and Opportunities in the Design of Age-Appropriate Drug Products;Herausforderungen und Chancen in der Gestaltung altersgerechter Arzneimittel

Zeitschrift fur Gerontologie und Geriatrie

Volumn 45, Issue 6, 2012, Pages 479-484

  Stegemann, Sven ^a  

^a CAPSUGEL   (France)

Author keywords

Age factor; Drug delivery; Geriatric; Medication adherence; Medicine

Indexed keywords

AGED; ARTICLE; DRUG DESIGN; DRUG INTERACTION; DRUG TOXICITY; FEMALE; HUMAN; MALE; POLYPHARMACY; RISK FACTOR;

AGED; AGED, 80 AND OVER; DRUG DESIGN; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HUMANS; MALE; POLYPHARMACY; RISK FACTORS;

EID: 84865714772     PISSN: 09486704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00391-012-0361-z     Document Type: Article

References (39)

1. Jaruzelski B, Loehr J, Holman R (2011) The global innovation 1000: why culture is key. Booz & Co Report 65
2. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185
3. (o A) (2010) Pharmaceutical key trends 2010. Report DMHC2599, Datamonitor
4. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715
5. Mullard A (2011) 2010 FDA drug approvals. Nat Rev Drug Discov 10:82-85
6. Kneller R (2010) The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 9:867-882
7. Snow V, Barry P, Fihn SD et al (2004) Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American college of physicians. Ann Intern Med 141:562-567
8. Maas J, Kamm W, Hauck G (2007) An integrated early formulation strategy - from hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 66:1-10
9. Hoffman AS (2008) The origin and evolution of "controlled" drug delivery systems. J Contr Rel 132:153-163
10. Swain S, Beg S, Singh A et al (2011) Advanced techniques for penetration enhancement in transdermal drug delivery systems. Curr Drug Deliv 8(4):456-473
11. Hohenegger M (2010) Novel and current treatment concepts using pulmonary drug delivery. Curr Pharm Design 16:2484-2492
12. Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9(4):384-398
13. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41(2):67-76
14. Bushardt RL, Massey EB, Simpson TW et al (2008) Polypharmacy: misleading, but manageable. Clin Interv Aging 3(2):383-389
15. Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncolo Hematol 48:133-143
16. Rodenhuis N, De Smet PAGM, Barends DM (2004) The rational of scored tablets as dosage form. Eur J Pharm Sci 21:305-308
17. (o A) (2009) FDA Tablet splitting: a risky practice. 21. July 2009 http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm171492.htm
18. Quinzler R, Gasse C, Schneider A et al (2006) The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 62:1065-1073
19. Atkin PA, Finnegan TP, Ogle SJ, Shenfield GM (1994) Functional ability of patients to manage medication packaging: a survey of geriatric inpatients. Age Ageing 23:113-116
20. Lee JK, Grace KA, Taylor AJ (2006) Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA 296(21):2563-2571
21. Klaver CW, Wolfs RCW, Vingerling JR et al (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population. Arch Ophathalmol 116:653-658
22. Wijk H, Berg S, Bergman B et al (2002) Colour perception among the very elderly related to visual and cognitive function. Scand J Caring Sci 16:91-102
23. Hersberger J (1997) Differenzierbarkeit und Präferenz von Kapselfarben bei älteren Menschen. Lizentiatsarbeit Universität Basel, Institut für Psychologie, November 1997
24. Perrig JW, Wippich W, Perrig-Chiello P (1993) Unbewußte Informationsbearbeitung. Verlag Hans Huber, Bern
25. Perrig-Chiello P, Perrig JW, Staehelin H et al (1994) IDA-Die Basler Interdisziplinäre Altersstudie
26. Stegemann S (2005) Colored capsules - a contribution to drug safety. Pharm Ind 67(9):1088-1095
27. Stegemann S, Gosch M, Breitkreutz J (o J) Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm (in press)
28. Kottke MK, Stetsko G, Rosenbaum SE, Rhodes CT (1990) Problems encountered by the elderly in the use of conventional dosage forms. J Geriatr Drug Ther 5(2):77-92
29. Payot V, Cordonier A-C, Marquis J et al (2011) Prevalence of patients' difficulties in swallowing solid SODF. Int J Clin Pharm 33:402
30. Paradiso LM, Roughead EE, Gilbert AL et al (2002) Crushing or atering medications: what's happening in residential aged-care facilities? Aust J Ageing 21(3):123-127
31. Strachan I, Greener M (2005) Medication related swallowing difficulties may be more common than we realize. Pharm Pract 15(10) 411-414
32. Clave P, Arreola V, Romea M et al (2008) Accuracy of the volume viscosity swallow test for clinical screening of oropharyngeal dysphagia and aspiration. Clin Nutri 27:806-815
33. Spomer N, Klingmann V, Stoltenberg I et al (2012) Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child 97:283-286
34. Metz DC, Vakily M, Dixit T, Mulford D (2009) Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pumb inhibitor therapy. Aliment Pharmacol Ther 29:928-937
35. Carneby-Mann G, Crary M (2005) Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 131(11):970-975
36. Breitkreutz J, Boos J (2007) Paediatric and geriatric drug delivery. Exp Opin Drug Deliv 4(1):37-45
37. Geriatric Medicine Society (2011) Expert meeting on geriatric medicines. March 16, 2011 http://www.geriatric-medicine.org/images/downloads/gme_meeting20110311.pdf
38. Guidance for Industry: container closure systems for packaging human drugs and biologics. FDA May 1999 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070551.pdf
39. Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364(11):985-987